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Fecal Microbiota Transplantation for recurrent Clostridium 
difficile infection
Raquel Casquero Galindo, Microbiology bachelor thesis (Universitat Autònoma de Barcelona)
MATERIALS AND METHODS
After Fecal Microbiota Transplantation:
• 90% of infection resolution, depending on the procedure characteristics of FMT:
• Restoration of the normal diversity of microbiota and bile acids in gut.
• Few adverse effects (like mild transient fever, as a result of temporary systematic
immune response to the applied bacteria)
RESULTS
• Clostridium difficile is a current issue, with high mortality and very high costs
• Consequently to the analysis of advantages/ disadvantages and classification as a
unapproved new drug by FDA, Fecal Microbiota Transplantation is systematically
recommended only for recurrent cases of Clostridium difficile infection.
• Nevertheless, is a safety process with a high efficacy rates (80-90% depending on
procedure characteristics)
• New generation FMT, like fecal pills or other methods, are under investigation for
replacing the FMT available nowadays.
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Figure 3: protocol of stool donor process9. NG (nasogastric), ND (nasoduodenal) 
Screening test to donor stool
• Blood analysis:
• Total blood count
• C-reactive protein
• Creatinine
• Liver enzyme levels
• Stool testing:
• C. difficile toxin A/B and culture
• Enteric pathogens
• Parasites (e.g., Giardia)
• HIV (1 and 2), HBV, HCV
• Other: illicit drugs, tattoos, other diseases (e.g.,
inflammatory bowel disease)
Filtered with 
clean gauzes, to 
remove large 
particulate 
matter 
Transferred to lab. 
within the first 6h. 
Advantages of FMT Disadvantages of FMT
• Inexpensive material (stool)
• High reported cure rate (average of 80-
90%)
• Insignificant adverse effects
• Fast response to the treatment (hours to
days)
• Antibiotic resistance avoided
• Corrected imbalance of the microbiota in
bowel
• Expensive screening for donors
• Laborious and time consuming technique
(laboratory technicians are required for the
screening of donor material)
• Invasive method of administration 
(nasoduodenal tube, colonoscopy, 
enemas,…)
• Possible long term effects (autoimmune
diseases, allergies and functional intestinal
diseases)
• Needing of standardized, licensed and ready
to use method.
• Clostridium difficile is an obligated anaerobic,
gram positive spore-forming bacterium that
belongs to Firmicutes group.
• Is the major causative agent for antibiotic-
associated diarrhea, representing 2,3% within
nosocomial infections with a high economic
significance.
• Its pathology is through the production of
toxin A (enterotoxin) and toxin B (cytotoxin).
Furthermore, some strains (PCR ribotype 027)
produces a binary toxin, which is related to
increased severity.
• Current treatment based on antibiotics:
Vancomycin, Metronidazol and Fidaxomicin
• Increased interest because of the high incidence and severity of CDI in the last 2 decades and
the high cure rates that FMT shows.
• FDA classified FMT as an unapproved new
drug (phase 1) which fits in a biological agent
and drug definition.
• Little is known about how it work, but
it’s thought that gut microbes can:
• Compete for niche exclusion
• Consumption of sialic acids
• Have a direct toxigenic activity
(bactericines like thuricin)
• Interfere with the lifecycle by the
metabolism of bile acids
Fecal Microbiota Transplantation (FMT)
OVERVIEW
• Using frozen stool (adding glycerol as a
cryoprotectant) instead fresh feces, because:
• It shows the same success rate, with no
significant side effects observed
• It decreases the donation times per
individual donor and can simplify some
practical aspects
• Investigation of oral treatment
• Good manufacturing practice (GMP) adapted
for production of therapeutic fecal microbiota.
• Synthetic communities of bacteria (culture
and administration of some strains) could be
used in a not distant future.
FUTURE DIRECTIONS10
DISCUSSION
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Table 2: list of advantages and disadvantages to compare for FMT extracted through different papers  
Criteria Treatment
First recurrence 125mg oral Vancomycin for
14 d
Second recurrence Pulsed Vancomycin:
• 125mg oral Vancomycin for 
7 wk
Three or more recurrences Consider fecal microbiota
therapy
Table 1: strategy for treatment recurrent CDI
Figure 5: Suspension of defined number of
bacteria for therapeutic intestinal microbiota
(GMP production by the University of
Minnesota)10
• Diverse spectrum of disease:
• Diarrhea
• Pseudomembranous and fulminant colitis
Clostridium difficile infection (CDI)1
Figure 6: Fecal frozen capsules by Dr. Elizabeth
Hohmann and Thomas Louie11,12
NG or ND 
tube
enema
Figure 1: illustration of
Clostridium difficile
from anaerobe blood
agar2.
Figure 2: representation of post FMT effects on microbiota in patients. Based on3-5
• Risk factors for Clostridium
difficile infection are: 
• Elderly
• prolonged length of 
hospital stay
• antibiotic exposure
• Immunosuppression
• other disease (diabetes, 
cirrhosis,…)
• Use of proton pump 
inhibitors  
Figure 4: Outcomes in patients with FMT for CDI. * V (Vancomycin), M (Metronidazol), AB (antibiotics). Based on6-8
